Obsidian Therapeutics Director Maria Fardis Receives Option Grant

What Happened
Maria Fardis, a director of Obsidian Therapeutics, was reported on Form 4 as receiving an award/grant of 37,653 derivative shares (reported at $0.00) on 2026-08-03. The filing classifies this as an acquisition (A) of a derivative instrument — specifically an option award — rather than an open-market purchase or sale. No cash was paid in connection with the reported grant (total reported value $0).

Key Details

• Transaction date: 2026-08-03; Form 4 filed: 2026-08-05 (appears timely under the two-business-day rule).
• Instrument: Derivative award/option for 37,653 shares; reported price $0.00.
• Vesting/exercise condition (footnote): vests and becomes exercisable on the earlier of (i) one-year anniversary of the grant or (ii) the Issuer’s next annual meeting following the grant, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, cashless exercise, gift, or tax-withholding event in the provided details.

Context
This is a standard option/award grant to a director and does not represent an immediate market purchase or sale. For retail investors, grant filings show compensation or retention incentives but are not direct bullish/bearish trades; the award vests over time and will only become exercisable if the vesting conditions are met.